We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has not lost interest in electronic data integrity, audit trails or computer system validation, even though it has stated it will exercise enforcement discretion regarding 21 CFR Part 11, experts stressed at FDAnews' recent FDA Information Management Summit in Bethesda, Md.
Although Guidant disagreed with the FDA’s recent observation of apparent software validation and electronic records control violations, the company said it would examine and strengthen the relevant in-house requirements and implementation guidelines to ensure compliance with 21 CFR Part 11.
The FDA is unlikely to complete its long-awaited revision of 21 CFR Part 11 — which regulates the use of electronic records and signatures — by the end of the year as industry observers had expected, an agency official said this month.
Three-quarters of the regulatory professionals polled in a recent survey expect to implement electronic common technical document (eCTD) submissions, up from 58 percent last year.
Drugmakers planning to submit electronic common technical documents (eCTDs) to the FDA will likely have to upgrade their systems, despite claims from the agency that system enhancements won’t be needed, says an industry consultant.
A recent warning letter citing 21 CFR Part 11 validation and control requirements sends a clear signal that the FDA intends to enforce the electronic records and signatures rule even as the agency moves toward revising it, industry experts say.
A recent warning letter citing 21 CFR Part 11 validation and control requirements is a clear signal that the FDA will enforce the electronic records and signatures regulation even as the agency moves toward revising it, industry experts say.
The FDA is aiming to finish its draft revision of Part 11 by the end of the year and make it available to the public in early 2006, according to sources close to the agency.
Sentrx has completed an FDA electronic submissions pilot and has begun sending individual case safety reports (ICSRs) from a leading pharmaceutical company to the agency through the Electronic Standards for the Transmission of Regulatory Information (ESTRI) Gateway, the technology company announced April 4.